Please login to the form below

Not currently logged in
Email:
Password:

Acambis patent boost

Transcripts reveal that ITC could come down on side of UK firm in dispute over smallpox vaccine

Shares in Acambis received a boost after lawyers from the US International Trade Commission (ITC) appeared to back the UK vaccine maker in its dispute with Danish rival, Bavarian Nordic, over patents for a smallpox vaccine.

The ITC released transcripts of the public sessions of a hearing on the case concerning the vaccine, called MVA.

Analyst Jonathan Senior at Evolution Securities told Reuters that although the ITC was yet to make a judgment, in its opening statement it had come down on the side of Acambis, saying the firm ìdidn't have a case to answerî.

ìThey're saying Bavarian Nordic's patents are not valid,î he said.

Acambis and Bavarian Nordic are fiercely competing for a lucrative US government contract to supply the vaccine.

In May, Acambis and US marketing partner Baxter, which manufactures the MVA vaccine, MVA3000, in Austria, filed opposition to a European patent granted to Bavarian Nordic regarding a weakened form of the vaccine, targeted at those who are immunocompromised, including those with HIV. Bavarian Nordic had claimed the two companies would be infringing its patents if they sell their smallpox vaccine to the US government.

ITC lawyers, acting as a third party, have told the ITC judge that Bavarian Nordic's patents are invalid and also unenforceable.

The ITC judge's initial determination on the case is expected around the end of August.

30th September 2008

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

COVID-19: the race to find a vaccine
How biopharma is working to bring an end to the pandemic...
Guiding star of science leads AstraZeneca to breakthrough in child tumour therapy
Global product lead George Kirk hails the triumph of selumetinib, which has just won FDA approval...
ACCOMPLISH MEANINGFUL HCP ENGAGEMENT ONLINE
The art of delivering valuable customer journeys aligned to your key messages in 2020...

Infographics